Recombinant human growth hormone and Gitelman's syndrome.
Am J Kidney Dis
; 33(4): 778-81, 1999 Apr.
Article
em En
| MEDLINE
| ID: mdl-10196023
ABSTRACT
Gitelman's syndrome is a primary renal tubular disorder with hypokalemic metabolic alkalosis, hypocalciuria, and magnesium deficiency. Short stature is one of clinical manifestations in children. The pathogenesis of short stature in Gitelman's syndrome is not known. To evaluate whether growth hormone (GH) is deficient and whether recombinant human GH (rhGH) improves growth rate, rhGH therapy was tried in a child with Gitelman's syndrome. Both height and body weight were less than the third percentile. Laboratory and radiologic findings suggested GH deficiency. During the first 6 months, rhGH therapy with potassium supplement markedly elevated growth rate from 3.8 cm/yr to 12.0 cm/yr. After cessation of rhGH, height increment markedly decreased to the pretreatment level of 3.6 cm/yr during the second 6 months. Additionally, hypomagnesemia was corrected after rhGH therapy. Accordingly, GH deficiency may contribute to short stature in children with Gitelman's syndrome, and rhGH therapy would be an excellent adjunctive treatment for short children with Gitelman's syndrome whose condition is resistant to conventional therapies in terms of growth.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Síndrome de Bartter
/
Hormônio do Crescimento Humano
Idioma:
En
Revista:
Am J Kidney Dis
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Coréia do Sul